Cargando…
Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion
The use of antivirals, corticosteroids, and IL-6 inhibitors has been recommended by the WHO to treat COVID-19. CP has also been considered for severe and critical cases. Clinical trials on CP have shown contradictory results, but an increasing number of patients, including immunocompromised ones, ha...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302885/ https://www.ncbi.nlm.nih.gov/pubmed/37374049 http://dx.doi.org/10.3390/life13061266 |
_version_ | 1785065148318220288 |
---|---|
author | Tomisti, Luca Angelotti, Francesca Lenzi, Mirco Amadori, Francesco Sarteschi, Giovanni Porcu, Anna Capria, Anna-Lisa Bertacca, Gloria Lombardi, Stefania Bianchini, Guido Vincenti, Antonella Cesta, Novella |
author_facet | Tomisti, Luca Angelotti, Francesca Lenzi, Mirco Amadori, Francesco Sarteschi, Giovanni Porcu, Anna Capria, Anna-Lisa Bertacca, Gloria Lombardi, Stefania Bianchini, Guido Vincenti, Antonella Cesta, Novella |
author_sort | Tomisti, Luca |
collection | PubMed |
description | The use of antivirals, corticosteroids, and IL-6 inhibitors has been recommended by the WHO to treat COVID-19. CP has also been considered for severe and critical cases. Clinical trials on CP have shown contradictory results, but an increasing number of patients, including immunocompromised ones, have shown benefits from this treatment. We reported two clinical cases of patients with prolonged COVID-19 infection and B-cell depletion who showed rapid clinical and virological recovery after the administration of CP. The first patient in this study was a 73-year-old female with a history of follicular non-Hodgkin lymphoma previously treated with bendamustine followed by maintenance therapy with rituximab. The second patient was a 68-year-old male with chronic obstructive pulmonary disease, bipolar disorder, alcoholic liver disease, and a history of mantellar non-Hodgkin lymphoma treated with rituximab and radiotherapy. After the administration of CP, both patients showed a resolution of symptoms, improvement of their clinical conditions, and a negative result of the nasopharyngeal swab test. The administration of CP might be effective in resolving symptoms and improving clinical and virological outcomes in patients with B-cell depletion and prolonged SARS-CoV2 infections. |
format | Online Article Text |
id | pubmed-10302885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103028852023-06-29 Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion Tomisti, Luca Angelotti, Francesca Lenzi, Mirco Amadori, Francesco Sarteschi, Giovanni Porcu, Anna Capria, Anna-Lisa Bertacca, Gloria Lombardi, Stefania Bianchini, Guido Vincenti, Antonella Cesta, Novella Life (Basel) Case Report The use of antivirals, corticosteroids, and IL-6 inhibitors has been recommended by the WHO to treat COVID-19. CP has also been considered for severe and critical cases. Clinical trials on CP have shown contradictory results, but an increasing number of patients, including immunocompromised ones, have shown benefits from this treatment. We reported two clinical cases of patients with prolonged COVID-19 infection and B-cell depletion who showed rapid clinical and virological recovery after the administration of CP. The first patient in this study was a 73-year-old female with a history of follicular non-Hodgkin lymphoma previously treated with bendamustine followed by maintenance therapy with rituximab. The second patient was a 68-year-old male with chronic obstructive pulmonary disease, bipolar disorder, alcoholic liver disease, and a history of mantellar non-Hodgkin lymphoma treated with rituximab and radiotherapy. After the administration of CP, both patients showed a resolution of symptoms, improvement of their clinical conditions, and a negative result of the nasopharyngeal swab test. The administration of CP might be effective in resolving symptoms and improving clinical and virological outcomes in patients with B-cell depletion and prolonged SARS-CoV2 infections. MDPI 2023-05-27 /pmc/articles/PMC10302885/ /pubmed/37374049 http://dx.doi.org/10.3390/life13061266 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Tomisti, Luca Angelotti, Francesca Lenzi, Mirco Amadori, Francesco Sarteschi, Giovanni Porcu, Anna Capria, Anna-Lisa Bertacca, Gloria Lombardi, Stefania Bianchini, Guido Vincenti, Antonella Cesta, Novella Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion |
title | Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion |
title_full | Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion |
title_fullStr | Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion |
title_full_unstemmed | Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion |
title_short | Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion |
title_sort | efficacy of convalescent plasma to treat long-standing covid-19 in patients with b-cell depletion |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302885/ https://www.ncbi.nlm.nih.gov/pubmed/37374049 http://dx.doi.org/10.3390/life13061266 |
work_keys_str_mv | AT tomistiluca efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT angelottifrancesca efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT lenzimirco efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT amadorifrancesco efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT sarteschigiovanni efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT porcuanna efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT capriaannalisa efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT bertaccagloria efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT lombardistefania efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT bianchiniguido efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT vincentiantonella efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion AT cestanovella efficacyofconvalescentplasmatotreatlongstandingcovid19inpatientswithbcelldepletion |